This Amedeo Smart survey is supported by AngelsInitiative.com.
AmedeoLeukemia |
|
Free Subscription
Cancer Chemother Pharmacol |
- October 2026
- AVINENI M, Habo YK, Habo NK, Elsayed AAR, et al
The role of tyrosine kinase inhibitors as a post-hematopoietic stem cell transplant continuation therapy for pediatric acute leukemia: a systematic review.
Cancer Chemother Pharmacol. 2026;96:126.
>> Share
September 2026 - TANNUMSAENG S, Anurathapan U, Sermcheep A, Kanjanakan P, et al
Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients.
Cancer Chemother Pharmacol. 2026;96:107.
>> Share
July 2026 - ABUMIYA M, Abe K, Watanabe A, Takahashi N, et al
Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis.
Cancer Chemother Pharmacol. 2026;96:72.
>> Share
- CHARAMIS J, Katzilakis N, Stiakaki E, Kyriakidis I, et al
Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights.
Cancer Chemother Pharmacol. 2026;96:69.
>> Share
June 2026 - RASMUSSEN ASB, Rank CU, Christensen IJ, Weimann A, et al
Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.
Cancer Chemother Pharmacol. 2026;96:65.
>> Share
May 2026 - VERHAGEN NE, Touw DCW, van den Heuvel JJMW, van den Broek PH, et al
Characterizing P-glycoprotein and Breast Cancer Resistance Protein interactions of asciminib among other tyrosine kinase inhibitors used in chronic myeloid leukemia.
Cancer Chemother Pharmacol. 2026;96:47.
>> Share
April 2026 - ONG WJ
Repurposing artesunate in acute myeloid leukemia: a pharmacokinetic rationale derived from antimalarial data.
Cancer Chemother Pharmacol. 2026;96:43.
>> Share
- LE TV, Dunn A, Holleran JL, Marino C, et al
Pharmacokinetics of venetoclax in a patient after whipple pancreaticoduodenectomy.
Cancer Chemother Pharmacol. 2026;96:42.
>> Share
March 2026 - RAHA SJ, Bhatia P, Bansal D, Trehan A, et al
Effect of high-dose methotrexate infusion duration on 48-hour drug levels and toxicity in children with acute lymphoblastic leukaemia: a quality-of-care study.
Cancer Chemother Pharmacol. 2026;96:24.
>> Share
January 2026 - YANAGIMACHI M, Iwano R, Keino D, Kimizuka Y, et al
Post-transplantation gilteritinib maintenance therapy and therapeutic drug monitoring in pediatric acute myeloid leukemia with FLT3-internal tandem duplication.
Cancer Chemother Pharmacol. 2026;96:10.
>> Share
December 2025 - BRILLAC C, Semiond D, Oprea C, Baruchel A, et al
Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics.
Cancer Chemother Pharmacol. 2025;95:116.
>> Share
October 2025 - COHEN IJ
Comment on: Dose adjustment strategy for high dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure toxicity relationship.
Cancer Chemother Pharmacol. 2025;95:95.
>> Share
August 2025 - SY SKB, Yang Y, Darstein C, Yoon DY, et al
Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.
Cancer Chemother Pharmacol. 2025;95:83.
>> Share
July 2025 - KOCH MR, Buhl Rasmussen AS, Als-Nielsen B, Duarte X, et al
DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia.
Cancer Chemother Pharmacol. 2025;95:76.
>> Share
- CHENG Y, Chen J, Vigil C, Khanzadeh S, et al
Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment.
Cancer Chemother Pharmacol. 2025;95:74.
>> Share
April 2025 - TANAKA Y, Ono R, Ashiarai M, Sakurai A, et al
The evaluation of the impact of NUDT15 variants on thiopurine metabolism in Japanese children with acute lymphoblastic leukemia.
Cancer Chemother Pharmacol. 2025;95:50.
>> Share
February 2025 - DARSTEIN C, Yoon D, Yang Y, Kapoor S, et al
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia.
Cancer Chemother Pharmacol. 2025;95:39.
>> Share
- OUERDANI A, Valenzuela B, Treijtel N, Haddish-Berhane N, et al
Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).
Cancer Chemother Pharmacol. 2025;95:38.
>> Share
- CAO A, Guan Y, Wang J, Li X, et al
Dose adjustment strategy for high-dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure-toxicity relationship.
Cancer Chemother Pharmacol. 2025;95:33.
>> Share
January 2025 - MAHER KR, Shafer D, Schaar D, Bandyopadhyay D, et al
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
Cancer Chemother Pharmacol. 2025;95:24.
>> Share
December 2024 - MANGOURA SA, Abdel-Raheem MH, Eltyb HA, Molla MS, et al
Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia.
Cancer Chemother Pharmacol. 2024;95:12.
>> Share
- MATSUI M, Yasu T, Makimoto A, Yuza Y, et al
Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML).
Cancer Chemother Pharmacol. 2024;95:1.
>> Share
September 2024 - CHRISTENSEN SR, Jensen CF, Heldrup J, Taylor Z, et al
Hypoalbuminemia in children with acute lymphoblastic leukemia: relation to asparaginase therapy and impact on high dose methotrexate elimination.
Cancer Chemother Pharmacol. 2024 Sep 21. doi: 10.1007/s00280-024-04713.
>> Share
July 2024 - RAHMAYANTI SU, Amalia R, Rusdiana T
Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients.
Cancer Chemother Pharmacol. 2024 Jul 13. doi: 10.1007/s00280-024-04694.
>> Share
June 2024 - CEREJA-PANTOJA KBC, de Brito Azevedo TC, Vinagre LWMS, de Moraes FCA, et al
Alterations in pharmacogenetic genes and their implications for imatinib resistance in Chronic Myeloid Leukemia patients from an admixed population.
Cancer Chemother Pharmacol. 2024 Jun 18. doi: 10.1007/s00280-024-04689.
>> Share
- GAIETTO A, Panetta JC, Pauley JL, Relling MV, et al
Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's Research Hospital.
Cancer Chemother Pharmacol. 2024;93:617-625.
>> Share
May 2024 - KOBAYASHI T, Sato H, Miura M, Fukushi Y, et al
Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia.
Cancer Chemother Pharmacol. 2024 May 23. doi: 10.1007/s00280-024-04673.
>> Share
March 2024 - DILLI BATCHA JS, Gota V, Matcha S, Raju AP, et al
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients.
Cancer Chemother Pharmacol. 2024 Mar 5. doi: 10.1007/s00280-024-04644.
>> Share
- QU W, Lu J, Ji Y, He Z, et al
Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia.
Cancer Chemother Pharmacol. 2024 Mar 2. doi: 10.1007/s00280-024-04642.
>> Share
February 2024 - MARCELLETTI JF, Sikic BI
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.
Cancer Chemother Pharmacol. 2024 Feb 26. doi: 10.1007/s00280-024-04656.
>> Share
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016
